metastatic pancreatic ductal carcinoma | sciencenewsnet.in

Breaking News

Interplay between mesenchymal stem cells and macrophages: Promoting bone tissue repair

Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19

Biological scaffold as potential platforms for stem cells: Current development and applications in wound healing

Effects of high glucose and severe hypoxia on the biological behavior of mesenchymal stem cells at various passages

Gossypol acetic acid regulates leukemia stem cells by degrading LRPPRC via inhibiting IL-6/JAK1/STAT3 signaling or resulting mitochondrial dysfunction

Expansion of human umbilical cord derived mesenchymal stem cells in regenerative medicine

Reveal more mechanisms of precondition mesenchymal stem cells inhibiting inflammation

Unveiling the role of hypoxia-inducible factor 2alpha in osteoporosis: Implications for bone health

Adipose-derived regenerative therapies for the treatment of knee osteoarthritis

Barcodes expand range of high-resolution sensor

26 Apr, 2024

New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer

November 11, 2020 sarah JonasResearch Results

New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.